Health Care Resource Utilization in Transthyretin Amyloid Cardiomyopathy Compared With Non-amyloid Heart Failure and the General Population.

Justin L Grodin¹, Ahmad Masri², Richard Wright³, Jean-François Tamby⁴, Heather Falvey⁴, Liana Hennum⁴, Margarita Udall⁴, Chaitanya Badwe⁵, Melissa Allison⁵, Rakesh Ramesh⁶, Shradha Sanghi⁶, Sandesh Dev⁷, Jose Nativi-Nicolau⁸

¹University of Texas Southwestern Medical Center Dallas TX USA.

²Oregon Health and Sciences University Portland OR USA.

³Pacific Heart Institute Santa Monica CA USA.

⁴BridgeBio Pharma, Inc. San Francisco CA USA.

⁵Definitive Healthcare New York NY USA.

⁶Definitive Healthcare Bengaluru Karnataka India.

⁷Arizona State University Scottsdale AZ USA.

⁸Mayo Clinic Jacksonville FL USA.

PubMed DOI

Abstract

BACKGROUND: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, fatal disease associated with a substantial health care system burden. The aim of this study was to compare health care resource utilization and associated costs among individuals with ATTR-CM, with non-amyloid heart failure (HF), and without HF in the United States. METHODS: Optum's de-identified Clinformatics Data Mart…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.